Payment overview · 2025
General Payments
$785.80
31 reported records · 9 companies
Healthcare provider profile · identity verified
Catherine Gu
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FLUSHING, NY · NPI 1073298634
Verified facts
What the public records show
CMS Open Payments records show Catherine Gu received $785.80 in general payments during 2025 across 31 reported records.
Gilead Sciences, Inc. accounted for 47.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Vemlidy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $372.04 | 47.4% | 10 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.34 | 13.8% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $78.58 | 10.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.18 | 8.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.44 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.67 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.89 | 4.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.11 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.55 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $785.80 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $108.34 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $78.58 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 308 | 156 |
| Losartan Potassium | Losartan Potassium | 221 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 98 |
| Donepezil Hcl | Donepezil Hcl | 173 | 80 |
| Metformin Hcl | Metformin Hcl | 128 | 63 |
| Alendronate Sodium | Alendronate Sodium | 107 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 49 |
| Naproxen | Naproxen | 90 | 75 |
| Omeprazole | Omeprazole | 79 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 44 |
| Meclizine Hcl | Meclizine Hcl | 70 | 58 |
| Finasteride | Finasteride | 57 | 24 |
| Trazodone Hcl | Trazodone Hcl | 53 | 35 |
| Gabapentin | Gabapentin | 50 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 40 |
| Diclofenac Epolamine | Diclofenac Epolamine | 46 | 29 |
| Famotidine | Famotidine | 44 | 39 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | 38 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | 20 |
| Simvastatin | Simvastatin | 39 | 21 |
| Jardiance | Empagliflozin | 37 | 15 |
| Carvedilol | Carvedilol | 34 | 14 |
| Azithromycin | Azithromycin | 32 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 26 |
| Eliquis | Apixaban | 31 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 26 |
| Farxiga | Dapagliflozin Propanediol | 29 | 12 |
| Mirtazapine | Mirtazapine | 29 | 15 |
| Glipizide Er | Glipizide | 27 | 15 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 16 |
| Vemlidy | Tenofovir Alafenamide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | 13 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 17 |
| Ibuprofen | Ibuprofen | 19 | 19 |
| Tradjenta | Linagliptin | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | 11 |
| Metronidazole | Metronidazole | 17 | 17 |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 12 |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Azelastine Hcl | Azelastine Hcl | 15 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $785.80 · 31 records | Gilead Sciences, Inc. | AIRSUPRA, CAPVAXIVE, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, KISUNLA, LINZESS, MOUNJARO, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, UBRELVY, Vemlidy, ZEPBOUND, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error